Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

89.86 -1.49 (-1.63%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

74 75 Next >

IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer

March 31, 2025

From AstraZeneca

Via Business Wire

Competitive Analysis In The ATTR-CM Field ↗

March 30, 2025

Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the...

Via Talk Markets

Topics Stocks / Equities

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug ↗

March 27, 2025

BridgeBio's acoramidis wins Japan's approval for ATTR-CM. Phase 3 data show a 42% reduction in key heart-related events. AstraZeneca's Alexion to market it.

Via Benzinga

J&J Drug Combo Outperforms Leading Lung Cancer Treatment In Survival Study ↗

March 26, 2025

Johnson & Johnson's MARIPOSA study shows Rybrevant plus Lazcluze significantly extends overall survival in first-line EGFR-mutated NSCLC over osimertinib.

Via Benzinga

Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements

March 27, 2025

EQNX::TICKER_START (NYSE:ATNM),(NYSE:BMY),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AZN) EQNX::TICKER_END

Via FinancialNewsMedia

New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings

March 25, 2025

From AstraZeneca

Via Business Wire

Forget the Correction: This Stock Is Defying the Sell-Off, and There Might Be More Upside Ahead ↗

March 23, 2025

Via The Motley Fool

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗

March 21, 2025

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.

Via Benzinga

Two Sectors Just Tried And Failed - And That’s Great For Us ↗

March 20, 2025

Technology and healthcare have both tried for a breakout and failed, courtesy of massive economic forces rocking the boat.

Via Talk Markets

Topics Stocks / Equities

A Potential Challenger For AstraZeneca's Blockbuster Lung Cancer Drug? ↗

March 20, 2025

AstraZeneca declined to comment without detailed clinical data on claims by Chinese makers of a competing experimental lung cancer drug.

Via Benzinga

Eventful Monday For AstraZeneca - What's Going On? ↗

March 17, 2025

AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for small cell lung cancer treatment.

Via Benzinga

AstraZeneca Seals Deal For EsoBiotec To Advance Cell Therapy: Details ↗

March 17, 2025

AstraZeneca PLC has agreed to acquire EsoBiotec SA, a biotech company specializing in in vivo cell therapies. The $1 billion deal includes an initial payment of $425 million, with additional contingent...

Via Benzinga

AstraZeneca and Erin Andrews team up to inspire fans to Get Body Checked Against Cancer

March 14, 2025

From AstraZeneca

Via Business Wire

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst ↗

March 13, 2025

H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.

Via Benzinga

EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity ↗

March 13, 2025

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management. Top-line results are expected by mid-2025.

Via Benzinga

Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion ↗

March 12, 2025

The company is looking to test a combination of the drug it acquired from Carmot Therapeutics and a amylin-based drug.

Via Investor's Business Daily

Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal ↗

March 12, 2025

Ionis grants Ono global rights to sapablursen for polycythemia vera in a deal worth up to $940M, including milestones and royalties on future sales.

Via Benzinga

One Week Is Currently Like A Decade In These Markets ↗

March 09, 2025

It’s what they call a “low dollar market” in that general conditions aren’t easy and there aren’t many slam dunk no-brainer setups.

Via Talk Markets

Topics ETFs Stocks / Equities

Is ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) suited for quality investing? ↗

March 08, 2025

A fundamental analysis of (NASDAQ:AZN): This article explores why quality investors may have a look at ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN)

Via Chartmill

AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients ↗

March 07, 2025

AstraZeneca's Imfinzi perioperative regimen improved event-free survival in gastric and GEJ cancer. The trial showed a strong trend in overall survival.

Via Benzinga

IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers

March 07, 2025

From AstraZeneca

Via Business Wire

Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst ↗

March 06, 2025

Kiniksa shifts focus to cardiovascular indications, halts abiprubart in Sjögren's, ends its AstraZeneca deal, and advances KPL-387 for recurrent pericarditis.

Via Benzinga

Inside The Quantum Computing Crash Triggered By Nvidia CEO — And What His Upcoming 'Quantum Day' May Bring ↗

March 06, 2025

Nvidia's CEO threw cold water on quantum computing by scoffing at its near-term utility. Quantum execs are sharpening their arguments.

Via Investor's Business Daily

Amgen Challenges Novo Nordisk's Ozempic And Eli Lilly's Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials ↗

March 06, 2025

Via Benzinga

Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis ↗

March 03, 2025

Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.

Via Benzinga

Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps

March 01, 2025

From AstraZeneca

Via Business Wire

IonQ CEO Fires Back At Nvidia's Jensen Huang: 'We Remain The 800 Pound Guerrilla' ↗

February 28, 2025

IonQ CEO Niccolo De Masi is confident that quantum computing will soon be the third leg of computing. With major partnerships and predicted GAAP revenue, IonQ is poised to be a leader in the industry.

Via Benzinga

Snowflake Expands Microsoft, OpenAI Partnership: Will Include Other Prominent Models Like Anthropic's Claude, Meta's Llama, And DeepSeek ↗

February 27, 2025

Snowflake unveiled its deeper partnership with Microsoft Corp during its earnings call and introduced its new AI agent Cortex.

Via Benzinga

Topics Artificial Intelligence Earnings

AstraZeneca's Investigational Cancer Drug Shows First-Line Benefit In Combination With Widely Cancer Medicines ↗

February 26, 2025

AstraZeneca's SERENA-6 trial shows camizestrant plus a CDK4/6 inhibitor improves progression-free survival in HR-positive, HER2-negative breast cancer.

Via Benzinga

Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial

February 26, 2025

From AstraZeneca

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

74 75 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.